Table 1

Characteristics of included literature

Author/year/refCountrySample size (T/C)Age (T/C)Drug concentration (T/C)Frequency of administration (T/C)Intervention measure (T/C)Intervention durationObjective sign baseline (mean±SD, T/C)Subjective symptom baseline (mean±SD, T/C)Outcome measures
Zhang X/ 201412 China8/812.56±8.970.1%One drop/time, twice dailyTacrolimus/
placebo
4 W17.3750±5.31507/
19.0000±5.57375
8.3750±2.24722/
8.3125±2.21265
Signs, symptoms
Pucci N/ 201513 Italy30/309.05±2.120.1%/1%One drop/time, 3 times dailyTacrolimus/
cyclosporine A
3 W6.016±1.133/
6.000±1.121
6.3±3.415/
6.566±3.349
Signs, symptoms, side effects, quality of life score,
Zanjani H/ 201714 Iran20/2010.9±3.4/
11.3±5.4
0.005%/ 1 000 000 IU/mLTwo drops/timeTacrolimus +placebo/
interferon α-2b+placebo
NA7.7±1.2/
8.9±1.2
9.6±0.8/
9.7±0.9
Signs, symptoms, side effects
Kumari R/ 201715 India16/168.06±1.94/
7.12±1.66
0.03%/0.05%Twice daily+4 times daily/ 4 times daily+twice dailyTacrolimus +placebo/
cyclosporine +placebo
6 W4.88±1.5/
4.5±1.15
7.06±2.59/
7.75±2.90
Signs, symptoms, side effects, recurrence rate
Xiang Q/ 201816 China28/2710.86±2.98/
10.93±3.51
NA/NAOne drop/time, twice daily/1 drop/time, 4 times dailyTacrolimus/ tobramycin dexamethasone1 W15.25±1.69/
15.19±1.57
11.21±2.25/
11±2.20
Signs, symptoms,
  • C, Control group; T, Trial group; W, weeks.